COMMUNIQUÉS West-GlobeNewswire

Route 92 Medical Announces $50 Million Series F Extension Equity Financing

23/09/2024 - 15:00

Funds from Novo Holdings will support global commercial expansion Novo Holdings’ Noel Jee joins Route 92 Board of Directors SAN MATEO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held [...]

Digital Utilities Ventures Reports Strong Fiscal Year 2024 - Advancing Leadership in Green Technologies

23/09/2024 - 15:00

MANKATO, Minn., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in sustainable energy and environmental technologies, recently announced its financial results and corporate [...]

T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture

23/09/2024 - 15:00

LEXINGTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted a [...]

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

23/09/2024 - 14:56

WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]

Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer

23/09/2024 - 14:55

– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance – – New PK/PD results demonstrate that istisociclib given at 80mg on a 4 [...]

Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform

23/09/2024 - 14:54

Opportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment Amsterdam, The Netherlands and Cambridge, Mass. and [...]

Interim Results for the Six Months Ended 30 June 2024

23/09/2024 - 14:42

Press release OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration progressing across UK [...]

Revolutionizing Surgery: SS Innovations International Inc. Celebrates 2,000 Procedures with its SSi Mantra Surgical Robotic System

23/09/2024 - 14:30

FORT LAUDERDALE, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), developer of innovative surgical robotic technologies dedicated to making [...]

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2

23/09/2024 - 14:30

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in [...]

Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024

23/09/2024 - 14:30

BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cerevance , a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief executive officer, will [...]

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

23/09/2024 - 14:17

FDA confirm s that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty [...]

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza

23/09/2024 - 14:00

The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary [...]

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

23/09/2024 - 14:00

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc [...]

European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement

23/09/2024 - 14:00

European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET - The European Microbiome Innovation for Health [...]

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

22/09/2024 - 16:00

Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

21/09/2024 - 10:15

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia , including TEV -‘ 749 Currently, there is no long-acting olanzapine [...]

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

21/09/2024 - 10:10

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia throu gh scientific and clinical advances that support optimal treatment options and decisions for [...]

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

21/09/2024 - 00:36

Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on positive [...]

Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)

21/09/2024 - 00:36

Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une [...]